DiaMedica Therapeutics Inc (DMAC) Quote

I don't understand the lack of interest. Multiple analysts project a stock price average of $18.50 within a year.

Is there a different message board somewhere with an interested discussion group?

SEC Form 4s - Multiple informative buys from insiders.

Very dead board, but I'll try once more.

I have felt for a couple of years that this is a very interesting biotech heading toward two phase 3 studies next year that both will have short time data collection periods leading to possible major deciions.

Company history highlighted by 50 years of research in the Pacific region.

May 6 company conference call initiated a sell off that seems to be a good entry point unless someone can explain to me what item in the call initiated the sell off. I cannot detect a red flag in the transcript of the call.

Secondary - 2.1M shares @ $4

https://newsfilter.io/a/7daf655cf66c24a2f6fef7ce63b85019

Not a terrible first day for a new secondary issuance; stock recovered almost 50% from a 9% sell off in pre-market. I want to learn more about the quality/reputation of the acquirers. If the likes of Wainwright or other hatchet shops are involved, we all know how this will turn out. Prefer buying at support sub $4, but a temp floor may now be in. We'll see.

Provisional Approval??

My understanding is that there is a new process in Australia that can accelerate the approval of promising drugs after a successful Phase 2 study whereby you can begin selling the drug and continue collecting data into a phase 4 to achieve final approval.

Since DMAC increased the stroke study to 100 patients which is supposed to report topline phase 2 results data in 1Q/20, I'm wondering if they are applying for this "provisional approval?"

Any information or thoughts about this possibility would be appreciated.

Anyone know where to find a list of the owners of this company...particularly the owners of the largest percentage of shares. Conference call indicated there were at least two Chinese entities who owned shares, but all I see in the SEC filings of institutional owners are not Chinese??

Back under $3

* * $DMAC Video Chart 06-20-2019 * *

Link to Video - click here to watch the technical chart video

Bad timing in IPO land. 1M traded in 4M offering...down 22+%.

Any upcoming catalyst to stabilize the bleeding? Would be nice to get a press release with some timelines surrounding the Chinese trials and possible length to commercialization.

I see Fosun Group signed an agreement with RVNC on Friday. I also see the Trump administration is trying to stop joint ventures between US and Chinese companies??

Ancient Chinese curse..."may you live in interesting times."

Per S1/A DiaMedica Therapeutics Inc.'s ticker on the Nasdaq is DMAC:

https://www.sec.gov/Archives/edgar/data/1401040/000143774918021321/dmtp20181127_s1a.htm

DMCA moved to the Nasdaq from the OTC:

http://otce.finra.org/DLDeletions

IPO info But incomplete because no mention of China agreement.

https://seekingalpha.com/article/4226691-diamedica-ipo-phase-2-target-market-14_4-billion

DMCAF one for 20 reverse split:

http://otce.finra.org/DLSymbolNameChanges

Can anyone effectively verify or dispute the info posted on Yahoo message board about some Zacks information concerning DMCAF being incorrect or incomplete that caused the recent selloff???

only down 20% since this epic call........

You must be pumpin this up to help dump those .31 cent Canadian private placement shares that are sellable at the end of the month....

DMCAF is one of the most talked about BIO plays on the canadian side...An American company trading on the venture. This little Bio play is about to head into the dollars...stay tuned!!

“The compound is used in Asia for an astonishing list of diseases, despite the fact that it’s extremely expensive.

The Asian form is also suboptimal as a Western drug candidate because it comes from pig pancreases and the urine of young humans. Using animal or urine sources is not just aesthetically distasteful, it introduces risks of contamination into the production process that tend to put off regulators.

DiaMedica solved that problem by developing a proprietary, genetically modified cell type that expresses enormous amounts of KLK1 at a fraction of the cost of existing cell technologies. Big Pharma had tried to do this for years, always failing.

These cells have allowed DiaMedica to synthesize a drug under standardized conditions that has enormous potential—not only as treatments for many diseases, but as a breakthrough anti-aging geroprotector”



“Think of recombinant tissue kallikrein, DiaMedica’s lead product, as being a blood-vessel opening, blood-flow promoting substance that is nature’s preferred way of enhancing perfusion (flow) in tissues. You don’t have to be a rocket scientist to think of disease states where flow is aberrant or altered or needs assistance, right? What if recombinant tissue kallikrein had a role in all or many of those settings? Stroke, heart attack, peripheral vascular disease, angina, hypertension, maybe even PULMONARY hypertension.”

John Mauldin’s Biotech company -- DiaMedica (TSXV:DMA; OTCQB:DMCAF)

Compound is blood vessel opening, blood flow promoting substance used in many situations but especially those suffering a stroke. A total of 40 published clinical studies.

Compound used in Asia coming from pig pancreases and urine from young humans at very high cost.

Diamedica’s improved the compound with a synthetic version at a fraction of the cost.



Mauldin Economics write-up https://tinyurl.com/yao9dl9d